FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Risperidone Orally Disintegrating Tablets, USP
Status: Discontinuation
»Therapeutic Categories: Pediatric; Psychiatry

Expand all

Mylan Pharmaceuticals Inc. (New 03/28/2017)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
0.25 mg, 28’s count (NDC 0378-6042-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.
0.5 mg, 28’s count (NDC 0378-6043-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.
1 mg, 28’s count (NDC 0378-6044-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.
2 mg, 28’s count (NDC 0378-6045-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.
3 mg, 28’s count (NDC 0378-6046-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.
4 mg, 28’s count (NDC 0378-6047-28) 03/28/2017 A business decision was made to discontinue manufacture of the drug product. The product discontinuation is not related to product quality, safety or efficacy.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English